Radioreceptor binding profile of the atypical antipsychotic olanzapine

Neuropsychopharmacology

Volumn 14, Issue 2, 1996, Pages 87-96

  Bymaster, Frank P ^a   Calligaro, David O ^a   Falcone, Julie F ^a   Marsh, Richard D ^a   Moore, Nicholas A ^a   Tye, Nicholas C ^a   Seeman, Philip ^c   Wong, David T ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c University of Toronto ^*

Author keywords

Antipsychotic; Binding profile; Clozapine; Dopamine; Haloperidol; Olanzapine; Org 5222; Risperidone; Seroquel

Indexed keywords

2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; BETA ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG LABELING; DRUG RECEPTOR BINDING; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030062260     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(94)00129-N     Document Type: Article

References (62)

1. 2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 16:517-525
2. 3H]SCH23390 binding in vivo. Eur J Pharmacol 120:143-144
3. Arnt J (1982): Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321-329
4. Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Holman S, The Olanzapine HGAD Study Group (1996): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 14:111-123
5. Bolden C, Cusack B, Richelson E (1992): Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576-580
6. 4H]idazoxan in rat brain. J Pharmacol Exp Ther 241:1092-1098
7. 3H]diazepam binding. Proc Natl Acad Sci USA 74:3805-3809
8. Byland DB, Snyder SH (1976): Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12:568-580
9. 1C sites. Eur J Pharmacol 191:93-96
10. Casey DE (1989): Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53
11. Chakrabarti JK, Horsman L, Hotten TM, Pullar IA, Tupper DE, Wright FC (1980): 4-Piperazinyl-10H-thieno[2,3-b] [1,5]benzodiazepines as potential neuroleptics. J Med Chem 23:878-884
12. 50) of an enzymatic reaction. Biochem Pharmacol 22:3090-3108
13. Chiodo LA, Bunney BS (1983): Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
14. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G (1987): The risks and benefits of olanzapine versus chlorpromazine. J Clin Psychopharm 7:377-384
15. 2 receptors: Implications for drug mechanism of action. Life Sci 39:2571-2580
16. 3 receptor antagonist GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881-894
17. Creese I, Burt DR, Snyder SH (1976) : Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
18. Davis JM, Casper R (1977): Antipsychotic drugs: Clinical pharmacology and therapeutic use. Drugs 14:260-282
19. De Lean A, Munson P, Rodbard D (1978): Simultaneous analysis of families of sigmoidal curves: Application to bioassay radioligand assay and physiological dose-response curves. Am J Physiol 234:E97-E102
20. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR (1991): Antagonist binding profiles of five cloned muscarinic receptor subtypes. J Pharmacol Exp Ther 256:727-733
21. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31
22. Fuller RW, Snoddy HD (1992): Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Res Comm Chem Path Pharmacol 77:87-93
23. 3H-prazosin to rat brain α-adrenergic receptors. Eur J Pharmacol 55:323-326
24. 2 receptor. Prog Neuro-Psychopharmacol Biol Psychiatry 12:559-568
25. Hemrick-Luecke SK, Bymaster FP, Falcone JF, Moore NA, Tye NC, Fuller RW (1993): Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Twenty-third Annual Society for Neuroscience Meeting, Washington, DC, pp 382, 158.9
26. Jenner P, Marsden CD (1983): Neuroleptics and tardive dyskinesia. In Coyle JT, Enna SJ (eds), Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives, New York, Raven, pp 223-253
27. Kane JM, Honigfeld G, Singer J, Meltzer H, The Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
28. Krupp P, Barnes P (1992): Clozapine-associated agranulocytosis: Risk and aetiology. Br J Psychiatry 160(Suppl 17): 38-40
29. 4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol Pharmacol 38:805-815
30. Lewander T, Westerbergh SE, Morrison D (1990): Clinical profile of remoxipride - A combined analysis of a comparative double-blind multi-centre trial programme. Acta Psychiatr Scand 82(Suppl 358):92-98
31. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988): Biochemical profiles of resperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
32. i values. J Pharmacol Exp Ther 251:238-246
33. Migler BA, Warawa EJ, Malick JB (1993): Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:299-307
34. Miller RJ, Hiley CR (1974) : Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature (Lond) 248:596-597
35. Moore NA, Tye NC, Axton MS, Risius FC (1992): The behavioral pharmacology of olanzapine a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
36. Moore NA, Calligara DO, Wong DT, Bymaster FP, Tye NC (1993): The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
37. Moore NA, Rees G, Sanger G, Tye NC (1994): Effect of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5: 196-202
38. Munson PJ, Rodbard JD (1980): Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239
39. Peroutka SJ, Snyder SH (1980): Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518-1522
40. 1 muscarine receptors. Cell Molec Neurobiol 8:181-192
41. 2 binding affinity. Neuropsychopharmacology 1:101-107
42. 3 receptor antagonist zatosetron decreases the number of spontaneously active AlO dopamine neurons. Eur J Pharmacol 205:113-116
43. Roose K, Gelders Y, Heylen S (1988): Risperidone (R 64 766) in psychotic patients a first clinical therapeutic exploration. Acta Psychiatr Belg 88:233-241
44. 1C receptors. J Pharmacol Exp Ther 260: 1361-1365
45. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994): Binding of typical and atypical antipsychotics agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
46. Saller CF, Salama AI (1993): Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:185-292
47. 4 receptors bind (+)-aporphines, suggesting neuroleptic role, Sulpiride not stereoselective. Eur J Pharmacol 233:173-174
48. Seeman P, Van Tol HHM (1993b): Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 6:602-608
49. Seeman P, Lee T, Chang-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Lond) 261:717-718
50. 3H-apomorphine to calf brain dopamine receptors. Eur J Pharmacol 55:137-142
51. 4 receptors elevated in schizophrenia. Nature (Lond) 365: 441-445
52. Siten JMA, Vrijmoed-de Vries MC (1992): Org 5222 Preliminary clinical results. In Meltzer HY (ed), Novel antipsychotic drugs, New York, Raven Press, pp 145-154
53. Stockton ME, Rasmussen K (1996): Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104
54. Tarsey D (1983): Neuroleptic-induced extrapyramidal reactions: Classification, description and diagnosis. Clin Neuropharmacol 6:S9-S26
55. 3H]mepyramine. Proc Natl Acad Sci USA 75:6290-6294
56. 4 receptor with high affinity for the antipsychotic clozapine. Nature (Lond) 350:610-614
57. 4) in rat forebrain. Mol Pharmacol 38: 267-273
58. White FJ, Wang RY (1983): Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057
59. 3H]muscimol, a potent gamma-aminobutyric acid agonist, to rat brain synaptosomal membranes using filtration assay. J Neurochem 32:713-718
60. Wong DT, Threlkeld PG, Robertson DW (1991): Affinities of fluoxetine, it enantiomers and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 5:43-47
61. Wong DT, Moore NA, Calligaro DO, Bymaster FP, Seeman P (1993): The preclinical pharmacology of olanzapine a novel antipsychotic. Ninth World Congress of Psychiatry, Rio de Janeiro, Brazil
62. Worms P, Broekkamp CLE, Lloyd K (1983): Behavioral effects of neuroleptics. In Coyle JT, Enna SJ (eds), Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives, New York, Raven, pp 93-117